title: Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
authors.forename: Keith B
authors.initials: KB
authors.lastname: Hoffman
authors.forename: Andrea
authors.initials: A
authors.lastname: Demakas
authors.forename: Colin B
authors.initials: CB
authors.lastname: Erdman
authors.forename: Mo
authors.initials: M
authors.lastname: Dimbil
authors.forename: P Murali
authors.initials: PM
authors.lastname: Doraiswamy
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D057225:Data Mining; D017277:Drug Approval; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D053139:Oseltamivir / Q000009:adverse effects* / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir